Your search for tofacitinib returned 13 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Older than 2 years remove
Home remove

Your search for tofacitinib returned 13 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Tofacitinib Effective in Phase 3 Psoriasis Retreatment Study

Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
ACR/ARHP Annual Meeting 2015

Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA

Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
News

Methotrexate Monotherapy, Combo Therapy Compared for RA

Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.
Features

May 2013 New Drug CME/CEU Review

This CME/CEU activity is designed to give clinicians a better understanding of the pharmacology, indications, contraindications, benefits/risk and clinical trials data of a broad spectrum of new agents and those that have been granted a new indication.
News

Tofacitinib Goes Head-to-Head with Adalimumab in RA Study

Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
News

Xeljanz Approved for Rheumatoid Arthritis

Pfizer announced that the FDA has approved Xeljanz (tofacitinib citrate) tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate.